MaxCyte rises on collaboration with Imugene for cancer medicines
23/01/2024 17:48
** Shares of cell engineering firm MaxCyte MXCT.O rise
~4.2% to $5.18
** Firm says it signed an agreement allowing Imugene
IMU.AX to use MaxCyte's Flow Electroporation technology and
ExPERT platform to develop its cancer medicines
** Says it is entitled to receive platform licensing fees
and program-related revenue in return
** Up to last close, stock down 9.3% in the last 12 months
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Recent news on Imugene
See all newsAustralia's Imugene rises on fresh responses in blood cancer drug trial
Brief: Imugene Ltd Says Leslie Chong Resigns As CEO
Australia's Imugene loses most in over 8-years on discounted placement
Brief: Imugene To Raise A$11.12 Million Via Placement At A$0.095 Per Share
Brief: Imugene Requests Trading Halt Pending Proposed Capital Raising Announcement